The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer

Paul W. Sperduto; Norbert Kased; David Roberge; Samuel T. Chao; Ryan Shanley; Xianghua Luo; Penny K. Sneed; John Suh; Robert J. Weil; Ashley W. Jensen; Paul D. Brown; Helen A. Shih; John Kirkpatrick; Laurie E. Gaspar; John B. Fiveash; Veronica Chiang; Jonathan P.S. Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta

doi:10.1007/s11060-013-1083-9

The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer

Paul W. Sperduto, Norbert Kased, David Roberge, Samuel T. Chao, Ryan Shanley, Xianghua Luo, Penny K. Sneed, John Suh, Robert J. Weil, Ashley W. Jensen, Paul D. Brown, Helen A. Shih, John Kirkpatrick, Laurie E. Gaspar, John B. Fiveash, Veronica Chiang, Jonathan P.S. Knisely, Christina Maria Sperduto, Nancy Lin, Minesh Mehta

Research output: Contribution to journal › Article › peer-review

137 Scopus citations

Abstract

Our group has previously published the Diagnosis-Specific Graded Prognostic Assessment (GPA) showing the prognostic factors associated with survival in patients with brain metastases (BM). The purpose of this study is to investigate the relationship of breast cancer subtype to the time interval from primary diagnosis (PD) to development of BM (TPDBM), number of BM at initial BM presentation and survival. We analyzed our previously described multi-institutional retrospective database of 865 breast cancer patients treated for newly-diagnosed BM from 1993 to 2010. Several factors found to be associated with survival were incorporated into the Breast-GPA, including tumor subtype. The GPA database was further analyzed to determine if the subtype correlated with the TPDBM, number of BM, and survival from PD. After exclusions for incomplete data, 383 patients remained eligible for analysis. The subtypes were approximated as follows: Luminal B: triple positive; HER2: HER2 positive/ER/PR negative; Luminal A; ER/PR positive/HER2 negative; Basal: triple negative. Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively. Tumor subtype is an important prognostic factor for survival in patients with breast cancer and BM. Although TPDBM is not an independent prognostic factor for survival (and thus not part of the Breast-GPA), the TPDBM does correlate with tumor subtype but does not correlate with the number of BM. Patients with Basal and HER2 tumor subtypes have short TPDBM. Prospective studies are needed to determine if screening brain MRIs are indicated in patients with Basal or HER2 subtypes.

Original language	English (US)
Pages (from-to)	467-472
Number of pages	6
Journal	Journal of neuro-oncology
Volume	112
Issue number	3
DOIs	https://doi.org/10.1007/s11060-013-1083-9
State	Published - May 2013

Bibliographical note

Funding Information:
Acknowledgments Dr. Mehta has served as a consultant to Abbott, Bristol-Meyers-Squibb, Elekta, Genentech, Merck, Novartis, Novo-cure, Tomotherapy and Viewray; he serves on the Board of Directors of Pharmacyclics, He holds stock options in Pharmacyclics and Ac-curay. Dr. Lin has served as a consultant to Novartis (\$10 K) and GlaxoSmithKline (\$10 K). Grant Support This research was supported in part by Grant W81XWH-062-0033 from the U.S. Department of Defense Breast Cancer Research Program, to RJW, and by NIH Grant P30-CA77598 utilizing the services of the Biostatistics Core, Masonic Cancer Center, University of Minnesota shared resource.

Keywords

Brain metastases
Breast cancer
Estrogen
Graded prognostic assessment
HER2
Progesterone
Prognosis
Radiation therapy
Stereotactic radiosurgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/s11060-013-1083-9

Find It

Find It at U of M Libraries

Cite this

Sperduto, P. W., Kased, N., Roberge, D., Chao, S. T., Shanley, R., Luo, X., Sneed, P. K., Suh, J., Weil, R. J., Jensen, A. W., Brown, P. D., Shih, H. A., Kirkpatrick, J., Gaspar, L. E., Fiveash, J. B., Chiang, V., Knisely, J. P. S., Sperduto, C. M., Lin, N., & Mehta, M. (2013). The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal of neuro-oncology, 112(3), 467-472. https://doi.org/10.1007/s11060-013-1083-9

Sperduto, PW, Kased, N, Roberge, D, Chao, ST, Shanley, R , Luo, X, Sneed, PK, Suh, J, Weil, RJ, Jensen, AW, Brown, PD, Shih, HA, Kirkpatrick, J, Gaspar, LE, Fiveash, JB, Chiang, V, Knisely, JPS, Sperduto, CM, Lin, N & Mehta, M 2013, 'The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer', Journal of neuro-oncology, vol. 112, no. 3, pp. 467-472. https://doi.org/10.1007/s11060-013-1083-9

@article{46e5b31394d04a2587b84e42d12982a7,

title = "The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer",

abstract = "Our group has previously published the Diagnosis-Specific Graded Prognostic Assessment (GPA) showing the prognostic factors associated with survival in patients with brain metastases (BM). The purpose of this study is to investigate the relationship of breast cancer subtype to the time interval from primary diagnosis (PD) to development of BM (TPDBM), number of BM at initial BM presentation and survival. We analyzed our previously described multi-institutional retrospective database of 865 breast cancer patients treated for newly-diagnosed BM from 1993 to 2010. Several factors found to be associated with survival were incorporated into the Breast-GPA, including tumor subtype. The GPA database was further analyzed to determine if the subtype correlated with the TPDBM, number of BM, and survival from PD. After exclusions for incomplete data, 383 patients remained eligible for analysis. The subtypes were approximated as follows: Luminal B: triple positive; HER2: HER2 positive/ER/PR negative; Luminal A; ER/PR positive/HER2 negative; Basal: triple negative. Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively. Tumor subtype is an important prognostic factor for survival in patients with breast cancer and BM. Although TPDBM is not an independent prognostic factor for survival (and thus not part of the Breast-GPA), the TPDBM does correlate with tumor subtype but does not correlate with the number of BM. Patients with Basal and HER2 tumor subtypes have short TPDBM. Prospective studies are needed to determine if screening brain MRIs are indicated in patients with Basal or HER2 subtypes.",

keywords = "Brain metastases, Breast cancer, Estrogen, Graded prognostic assessment, HER2, Progesterone, Prognosis, Radiation therapy, Stereotactic radiosurgery",

author = "Sperduto, {Paul W.} and Norbert Kased and David Roberge and Chao, {Samuel T.} and Ryan Shanley and Xianghua Luo and Sneed, {Penny K.} and John Suh and Weil, {Robert J.} and Jensen, {Ashley W.} and Brown, {Paul D.} and Shih, {Helen A.} and John Kirkpatrick and Gaspar, {Laurie E.} and Fiveash, {John B.} and Veronica Chiang and Knisely, {Jonathan P.S.} and Sperduto, {Christina Maria} and Nancy Lin and Minesh Mehta",

note = "Funding Information: Acknowledgments Dr. Mehta has served as a consultant to Abbott, Bristol-Meyers-Squibb, Elekta, Genentech, Merck, Novartis, Novo-cure, Tomotherapy and Viewray; he serves on the Board of Directors of Pharmacyclics, He holds stock options in Pharmacyclics and Ac-curay. Dr. Lin has served as a consultant to Novartis (\$10 K) and GlaxoSmithKline (\$10 K). Grant Support This research was supported in part by Grant W81XWH-062-0033 from the U.S. Department of Defense Breast Cancer Research Program, to RJW, and by NIH Grant P30-CA77598 utilizing the services of the Biostatistics Core, Masonic Cancer Center, University of Minnesota shared resource.",

year = "2013",

month = may,

doi = "10.1007/s11060-013-1083-9",

language = "English (US)",

volume = "112",

pages = "467--472",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer

AU - Sperduto, Paul W.

AU - Kased, Norbert

AU - Roberge, David

AU - Chao, Samuel T.

AU - Shanley, Ryan

AU - Luo, Xianghua

AU - Sneed, Penny K.

AU - Suh, John

AU - Weil, Robert J.

AU - Jensen, Ashley W.

AU - Brown, Paul D.

AU - Shih, Helen A.

AU - Kirkpatrick, John

AU - Gaspar, Laurie E.

AU - Fiveash, John B.

AU - Chiang, Veronica

AU - Knisely, Jonathan P.S.

AU - Sperduto, Christina Maria

AU - Lin, Nancy

AU - Mehta, Minesh

N1 - Funding Information: Acknowledgments Dr. Mehta has served as a consultant to Abbott, Bristol-Meyers-Squibb, Elekta, Genentech, Merck, Novartis, Novo-cure, Tomotherapy and Viewray; he serves on the Board of Directors of Pharmacyclics, He holds stock options in Pharmacyclics and Ac-curay. Dr. Lin has served as a consultant to Novartis (\$10 K) and GlaxoSmithKline (\$10 K). Grant Support This research was supported in part by Grant W81XWH-062-0033 from the U.S. Department of Defense Breast Cancer Research Program, to RJW, and by NIH Grant P30-CA77598 utilizing the services of the Biostatistics Core, Masonic Cancer Center, University of Minnesota shared resource.

PY - 2013/5

Y1 - 2013/5

N2 - Our group has previously published the Diagnosis-Specific Graded Prognostic Assessment (GPA) showing the prognostic factors associated with survival in patients with brain metastases (BM). The purpose of this study is to investigate the relationship of breast cancer subtype to the time interval from primary diagnosis (PD) to development of BM (TPDBM), number of BM at initial BM presentation and survival. We analyzed our previously described multi-institutional retrospective database of 865 breast cancer patients treated for newly-diagnosed BM from 1993 to 2010. Several factors found to be associated with survival were incorporated into the Breast-GPA, including tumor subtype. The GPA database was further analyzed to determine if the subtype correlated with the TPDBM, number of BM, and survival from PD. After exclusions for incomplete data, 383 patients remained eligible for analysis. The subtypes were approximated as follows: Luminal B: triple positive; HER2: HER2 positive/ER/PR negative; Luminal A; ER/PR positive/HER2 negative; Basal: triple negative. Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively. Tumor subtype is an important prognostic factor for survival in patients with breast cancer and BM. Although TPDBM is not an independent prognostic factor for survival (and thus not part of the Breast-GPA), the TPDBM does correlate with tumor subtype but does not correlate with the number of BM. Patients with Basal and HER2 tumor subtypes have short TPDBM. Prospective studies are needed to determine if screening brain MRIs are indicated in patients with Basal or HER2 subtypes.

AB - Our group has previously published the Diagnosis-Specific Graded Prognostic Assessment (GPA) showing the prognostic factors associated with survival in patients with brain metastases (BM). The purpose of this study is to investigate the relationship of breast cancer subtype to the time interval from primary diagnosis (PD) to development of BM (TPDBM), number of BM at initial BM presentation and survival. We analyzed our previously described multi-institutional retrospective database of 865 breast cancer patients treated for newly-diagnosed BM from 1993 to 2010. Several factors found to be associated with survival were incorporated into the Breast-GPA, including tumor subtype. The GPA database was further analyzed to determine if the subtype correlated with the TPDBM, number of BM, and survival from PD. After exclusions for incomplete data, 383 patients remained eligible for analysis. The subtypes were approximated as follows: Luminal B: triple positive; HER2: HER2 positive/ER/PR negative; Luminal A; ER/PR positive/HER2 negative; Basal: triple negative. Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively. Tumor subtype is an important prognostic factor for survival in patients with breast cancer and BM. Although TPDBM is not an independent prognostic factor for survival (and thus not part of the Breast-GPA), the TPDBM does correlate with tumor subtype but does not correlate with the number of BM. Patients with Basal and HER2 tumor subtypes have short TPDBM. Prospective studies are needed to determine if screening brain MRIs are indicated in patients with Basal or HER2 subtypes.

KW - Brain metastases

KW - Breast cancer

KW - Estrogen

KW - Graded prognostic assessment

KW - HER2

KW - Progesterone

KW - Prognosis

KW - Radiation therapy

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84885058143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885058143&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1083-9

DO - 10.1007/s11060-013-1083-9

M3 - Article

C2 - 23462853

AN - SCOPUS:84885058143

SN - 0167-594X

VL - 112

SP - 467

EP - 472

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 3

ER -

The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this